IOL Chemicals and Pharmaceuticals Limited has informed the Exchange regarding a press release dated May 16, 2025, titled "Financial Results for the quarter and year ended 31st March 2025".
IOLCP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts less than Nifty Microcap 250 and 0.1 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
IOL Chemicals and Pharmaceuticals announced its Q4 and full-year FY25 results. In Q4 FY25, revenue grew 4.7% YoY to ₹527.8 Cr, EBITDA rose 17.1% to ₹67.5 Cr, and profit after tax (PAT) climbed 12.2% to ₹31.6 Cr, with EBITDA margin expanding by 141 basis points to 12.7%. For the full year FY25, however, revenue declined to ₹2,079.2 Cr from ₹2,132.8 Cr in FY24, while EBITDA fell to ₹224.6 Cr from ₹261.6 Cr and PAT dropped sharply to ₹101.0 Cr from ₹135.4 Cr, a 25% decline. FY25 EBITDA margin compressed by 140 basis points to 10.7%, and gross margin fell 160 bps to 33.8%, reflecting pricing pressure and competitive intensity. Operational highlights included commissioning of a new 10,800 MTPA Paracetamol unit, Clopidogrel capacity expansion, EDQM certifications, and entry into the China market for Ibuprofen exports.
Q4 shows a clear recovery with margin expansion and double-digit profit growth, but the full-year picture is weak, with revenue, EBITDA, and PAT all declining despite stable volumes. Investors may see the quarter as a sign of stabilisation, though the FY25 PAT decline of about 25% and margin compression could weigh on near-term sentiment until the new Paracetamol capacity starts contributing meaningfully.